Hospital
ST Lukes - ST Vincents Healthcare
ST Lukes - ST Vincents Healthcare was paid $6.40M by Medicaid between Jan 2018 and Mar 2022, across 151 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoST LUKES - ST VINCENTS HEALTHCARE
JACKSONVILLE, FL 32216
JACKSONVILLE, FL 32216
33aNPI1396926747assigned 11/14/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.40M
24GClaims218,024
24DCodes billed151
24AFirst – last monthJan 2018 – Mar 2022
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#72 of 163
Median peer was paid$4.77M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,707 | $188K | |
| 2019 | 57,657 | $1.58M | |
| 2020 | 58,983 | $1.80M | |
| 2021 | 70,314 | $2.31M | |
| 2022 | 12,363 | $519K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 16,262 | 11,678 | $928K |
| 36415 | Collection of venous blood by venipuncture | 8.0% | 11,515 | 7,707 | $515K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.2% | 8,816 | 6,461 | $459K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.2% | 1,605 | 1,212 | $458K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.3% | 5,569 | 4,824 | $403K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 4,424 | 3,627 | $316K |
| 59025 | Fetal non-stress test | 4.1% | 1,944 | 1,309 | $263K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.0% | 4,906 | 4,325 | $259K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.1% | 1,256 | 989 | $199K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.9% | 2,685 | 2,168 | $188K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 2,879 | 2,118 | $174K |
| 80053 | Comprehensive metabolic panel | 2.7% | 8,689 | 6,495 | $171K |
139 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.6% | 1,700 | $167K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.4% | 316 | $150K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 2,032 | $132K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 4,840 | $128K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.5% | 1,138 | $97K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 7,056 | $92K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 901 | $81K |
| 81025 | 1.1% | 3,448 | $73K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 810 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,125 | $55K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 424 | $54K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 645 | $52K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,309 | $52K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 850 | $51K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 683 | $48K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,258 | $47K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 668 | $40K |
| 82962 | <1% | 2,542 | $37K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 539 | $29K |
| 86901 | <1% | 1,039 | $27K | |
| G0378 | Hospital observation service, per hour | <1% | 2,736 | $27K |
| A9270 | Non-covered item or service | <1% | 3,938 | $25K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,916 | $25K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 96 | $24K |
| 81001 | <1% | 5,683 | $23K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,646 | $22K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 66 | $21K |
| 87081 | <1% | 722 | $21K | |
| 87210 | <1% | 1,014 | $19K | |
| 87400 | <1% | 1,875 | $19K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,480 | $18K |
| 93017 | <1% | 364 | $18K | |
| 76642 | <1% | 261 | $17K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 41 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,527 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 319 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,937 | $12K |
| 72131 | <1% | 169 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 141 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,540 | $11K |
| 81003 | <1% | 2,233 | $11K | |
| 96376 | <1% | 979 | $11K | |
| 86850 | <1% | 460 | $9K | |
| 86900 | <1% | 1,027 | $9K | |
| 72100 | <1% | 315 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 707 | $7K |
| 84112 | <1% | 40 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,654 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,861 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,052 | $6K |
| 82731 | <1% | 28 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 657 | $6K |
| 73610 | <1% | 159 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,610 | $5K |
| 73630 | <1% | 237 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 534 | $5K |
| 84702 | <1% | 1,214 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 129 | $5K |
| 85610 | <1% | 1,711 | $5K | |
| 73030 | <1% | 154 | $4K | |
| 84484 | <1% | 4,309 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 172 | $4K |
| 95816 | <1% | 35 | $4K | |
| 76801 | <1% | 416 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,076 | $3K |
| 73130 | <1% | 97 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,629 | $3K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 31 | $3K |
| 85730 | <1% | 1,107 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,017 | $3K |
| 72040 | <1% | 72 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 116 | $3K |
| 93971 | <1% | 172 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 360 | $2K |
| 73562 | <1% | 187 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,553 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,134 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,552 | $2K |
| 97161 | <1% | 46 | $2K | |
| 83735 | <1% | 788 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,018 | $2K |
| 83690 | <1% | 3,158 | $2K | |
| 83605 | <1% | 1,324 | $2K | |
| 94060 | <1% | 25 | $2K | |
| 84703 | <1% | 2,796 | $1K | |
| 85379 | <1% | 844 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,378 | $1K |
| 87077 | <1% | 60 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 523 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 425 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 652 | $917.72 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 368 | $747.05 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 963 | $647.28 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,258 | $554.27 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 985 | $549.15 |
| 80061 | Lipid panel | <1% | 52 | $486.13 |
| 83880 | <1% | 947 | $482.30 | |
| 80076 | <1% | 194 | $457.11 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 269 | $434.03 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 451 | $302.89 |
| 87634 | <1% | 188 | $219.17 | |
| 87186 | <1% | 194 | $219.06 | |
| 80329 | <1% | 122 | $152.36 | |
| 87807 | <1% | 99 | $140.41 | |
| 80320 | <1% | 266 | $138.89 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 532 | $122.18 |
| 84145 | <1% | 99 | $106.54 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 43 | $94.79 |
| 87040 | <1% | 275 | $61.30 | |
| 88342 | <1% | 166 | $33.87 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 88 | $14.52 |
| 86140 | <1% | 52 | $6.61 | |
| 87430 | <1% | 734 | $2.61 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 164 | $0.02 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 56 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 235 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 243 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 107 | $0.00 |
| 86803 | 0% | 41 | $0.00 | |
| 87147 | 0% | 51 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 36 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 103 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 16 | $0.00 |
| 85652 | 0% | 18 | $0.00 | |
| 85027 | 0% | 12 | $0.00 | |
| 82077 | 0% | 77 | $0.00 | |
| 94762 | 0% | 23 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 60 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 18 | $0.00 |
| 86703 | 0% | 41 | $0.00 | |
| 90714 | 0% | 15 | $0.00 | |
| 87641 | 0% | 17 | $0.00 | |
| 82010 | 0% | 17 | $0.00 | |
| 82248 | 0% | 30 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 42 | $0.00 |
| 94729 | 0% | 26 | $0.00 | |
| 94726 | 0% | 23 | $0.00 | |
| 77062 | 0% | 18 | $0.00 | |
| 76000 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKRAFT, JEREMY (DIRECTOR- NET REVENUE)